da Vinci单孔机器人经肛微创手术治疗直肠癌的初期病例系列经验
该单中心病例系列纳入2021年4月至2023年2月连续14例接受单孔机器人经肛微创手术(SPR-TAMIS)切除直肠癌的患者,评估技术可行性与肿瘤学结局。中位年龄72岁,中位肿瘤直径2.7 cm,93%获阴性切缘,中位手术时间175分钟、住院5天,无中转、无死亡及重大并发症,24个月随访无复发,提示对选择性早期直肠癌安全可行。
要点
- SPR-TAMIS对选择性早期直肠癌技术上可行,全层切除且标本无碎裂。
- 93%病例获阴性切缘,1例需进一步切除;无术中中转。
- 无死亡及重大并发症,仅1例(7.1%)Clavien-Dindo I级伤口裂开。
核心结论
- 初期经验显示SPR-TAMIS对选择性早期直肠癌是安全可行的手术,经肛入路提供增强视野和稳定操控性。
研究设计与样本
- 单中心连续病例系列,纳入2021年4月至2023年2月共14例接受SPR-TAMIS的直肠癌患者。
- 收集患者数据、手术细节和临床结局数据以评估安全性和可行性。
主要发现
- 中位年龄72岁,所有病例完成全层切除且标本无碎裂。
- 中位肿瘤直径2.7 cm,肿瘤位置距肛缘近端10 cm至远端7 cm之间。
- 93%病例获阴性切缘,1例需进一步切除。
- 中位手术时间175分钟,中位住院时间5天。
- 无术中中转、无死亡、无重大术后并发症;1例(7.1%)出现Clavien-Dindo I级伤口裂开。
临床怎么用
- SPR-TAMIS可作为选择性早期直肠癌的经肛切除选项,尤其适用于较大或更近端病灶的切除。
- 术前应评估肿瘤大小和位置,术中确保全层切除及标本完整以保障切缘阴性。
局限性
- 样本量小(14例),为单中心初期经验,结论需更大样本验证。
- 随访24个月,长期肿瘤学结局尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transanal minimally invasive surgery (TAMIS) is widely used for rectal lesion excision. Robot-assisted TA TAMIS (R-TAMIS) may improve surgical ergonomics. The introduction of the da Vinci Single-Port (SP) robot, designed for endoluminal surgery, has brought new possibilities. Our primary objective herein was to assess the technical and oncological feasibility and efficacy of Single-port robotic TAMIS (SPR-TAMIS) in rectal cancer excision. The secondary objective was to analyze the perioperative outcomes. MATERIALS AND METHODS: We included 14 consecutive patients with rectal cancer who underwent SPR-TAMIS between April 2021 and February 2023. Patient data, surgical details, and clinical outcome data were collected to assess the safety and feasibility of SPR-TAMIS. RESULTS: The median participant age was 72 years, and full-thickness excision was performed without specimen fragmentation in all cases. The median tumor diameter was 2.7 cm, positioned between 10 cm proximally and 7 cm distally from the anal verge. Negative margins were achieved in 93% of cases, with one case requiring further resection. The median operative time was 175 min, and the median hospital stay was 5 days. No intraoperative conversion from SPR-TAMIS to laparoscopic or conventional transanal excision was required. No mortalities or major postoperative complications occurred; however, one patient (7.1%) experienced minor morbidity manifesting as wound dehiscence (Clavien-Dindo grade I). No recurrence was observed during the 24-month follow-up. CONCLUSIONS: In our early experience, SPR-TAMIS is a safe and feasible surgery for selected early stage rectal cancers, offering enhanced visualization and stable maneuverability transanally. This platform may have potential advantages for the excision of larger or more proximal lesions.
引用
- Woo JS, Cho MJ, Park IK, et al. Initial case series experience with robotic-assisted transanal minimally invasive surgery performed with da Vinci single-port system for the excision of rectal cancer. Surg Endosc. 2024. PMID: 39160313. doi:10.1007/s00464-024-11142-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。